Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
68 hedge funds and large institutions have $27.1M invested in Seelos Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 3 closing their positions.
481% more call options, than puts
Call options by funds: $749K | Put options by funds: $129K
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
77% more capital invested
Capital invested by funds: $15.3M → $27.1M (+$11.7M)
13% more funds holding
Funds holding: 60 → 68 (+8)
15% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WE
Wealth Effects
Boston,
Massachusetts
|
+$604K |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$517K |
| 3 |
EWA
EP Wealth Advisors
Torrance,
California
|
+$173K |
| 4 |
GJL
Gendell Jeffrey L
|
+$90.2K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$48.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$378K |
| 2 |
Millennium Management
New York
|
-$142K |
| 3 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$93.7K |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$69.4K |
| 5 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
-$34.6K |
SEEL Hedge Fund Activity: Q2 2023 in Review
68 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q2 2023, worth a combined $27.1M — up 77% from $15.3M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new SEEL positions and 3 closed out — a net gain of 9 holders — while 11 added to existing stakes and 13 trimmed.
The largest buyer was Wealth Effects, adding an estimated $604K. The largest seller was Mirae Asset Global Investments, cutting an estimated $378K.
- 68 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q2 2023, up from 60 in Q1 2023.
- Funds reported $27.1M of Seelos Therapeutics, Inc. Common Stock stock for Q2 2023, up 77% quarter-over-quarter.
- 12 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q2 2023 and 3 closed out, a net change of +9 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q2 2023 was Wealth Effects, an estimated $604K added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q2 2023 was Mirae Asset Global Investments, an estimated $378K sold.
Based on aggregated 13F filings for Q2 2023.